PROCEPT BioRobotics/$PRCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Ticker
$PRCT
Sector
Primary listing
Employees
888
Headquarters
Website
PRCT Metrics
BasicAdvanced
$1.4B
-
-$1.72
1.02
-
Price and volume
Market cap
$1.4B
Beta
1.02
52-week high
$66.85
52-week low
$19.35
Average daily volume
1.9M
Financial strength
Current ratio
6.845
Quick ratio
5.624
Long term debt to equity
20.846
Total debt to equity
21.451
Interest coverage (TTM)
-28.96%
Profitability
EBITDA (TTM)
-97.618
Gross margin (TTM)
63.70%
Net profit margin (TTM)
-31.02%
Operating margin (TTM)
-33.71%
Effective tax rate (TTM)
-0.20%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-12.46%
Return on equity (TTM)
-24.89%
Valuation
Price to revenue (TTM)
4.358
Price to book
3.7
Price to tangible book (TTM)
3.73
Price to free cash flow (TTM)
-23.011
Free cash flow yield (TTM)
-4.35%
Free cash flow per share (TTM)
-1.05
Growth
Revenue change (TTM)
37.22%
Earnings per share change (TTM)
-1.89%
3-year revenue growth (CAGR)
60.14%
3-year earnings per share growth (CAGR)
-4.30%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
PRCT News
AllArticlesVideos
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Business Wire·18 hours ago
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire·1 day ago
ATTENTION PRCT Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
Newsfile Corp·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PROCEPT BioRobotics stock?
PROCEPT BioRobotics (PRCT) has a market cap of $1.4B as of March 11, 2026.
What is the P/E ratio for PROCEPT BioRobotics stock?
The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of March 11, 2026.
Does PROCEPT BioRobotics stock pay dividends?
No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of March 11, 2026.
When is the next PROCEPT BioRobotics dividend payment date?
PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.